{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:37:17Z","timestamp":1792629437856,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170021"],"award-info":[{"award-number":["82170021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jfma.2025.01.021","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:15:32Z","timestamp":1738322132000},"page":"379-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Small airways dysfunction in severe asthma: Current treatment approaches and future directions"],"prefix":"10.1016","volume":"125","author":[{"given":"Nishan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Xianyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-9474","authenticated-orcid":false,"given":"Hanxiang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jfma.2025.01.021_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S2213-2600(20)30363-5","article-title":"The genetics of asthma and the promise of genomics-guided drug target discovery","volume":"8","author":"El-Husseini","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib4","doi-asserted-by":"crossref","first-page":"s36","DOI":"10.7861\/clinmedicine.18-2-s36","article-title":"Diagnosis and treatment of severe asthma: a phenotype-based approach","volume":"18","author":"Jones","year":"2018","journal-title":"Clin Med"},{"key":"10.1016\/j.jfma.2025.01.021_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107168","article-title":"Anatomical and histopathological approaches to asthma phenotyping","volume":"210","author":"Erjef\u00e4lt","year":"2023","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib6","first-page":"171","article-title":"Small airways in asthma: pathophysiology, identification and management. Chinese medical journal pulmonary and","volume":"1","author":"Toumpanakis","year":"2023","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaci.2012.12.1567","article-title":"Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review","volume":"131","author":"van der Wiel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jfma.2025.01.021_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107532","article-title":"Small airways in asthma: from inflammation and pathophysiology to treatment response","volume":"222","author":"Siora","year":"2024","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MCP.0000000000000018","article-title":"The role of small airway disease in asthma","volume":"20","author":"Bjermer","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2332\/allergolint.55.305","article-title":"Reduction of eosinophils in small airways by inhaled steroids is insufficient in patients with adult asthma","volume":"55","author":"Tanaka","year":"2006","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1164\/ajrccm\/143.1.138","article-title":"Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma","volume":"143","author":"Saetta","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.200407-949OC","article-title":"Relationship of small airway chymase-positive mast cells and lung function in severe asthma","volume":"171","author":"Balzar","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Pt 1","key":"10.1016\/j.jfma.2025.01.021_bib14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0091-6749(99)70474-4","article-title":"Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals","volume":"103","author":"Taha","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"159","key":"10.1016\/j.jfma.2025.01.021_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0186-2020","article-title":"Structure and function of small airways in asthma patients revisited","volume":"30","author":"van den Bosch","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"17","key":"10.1016\/j.jfma.2025.01.021_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e36124","article-title":"Small airway inflammation in atypical asthma","volume":"10","author":"Han","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.jfma.2025.01.021_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1164\/rccm.200403-305OC","article-title":"Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma","volume":"170","author":"Mauad","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jaip.2022.12.040","article-title":"Impaired respiratory system resistance and reactance are associated with bronchial wall thickening in persistent asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.coph.2010.06.004","article-title":"Airway remodeling in asthma","volume":"10","author":"Halwani","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100628","article-title":"Phenotypic clusters on computed tomography reflects asthma heterogeneity and severity","volume":"15","author":"Kim","year":"2022","journal-title":"World Allergy Org J"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global initiative for asthma strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/02770901003605340","article-title":"Use of long-acting \u03b2-agonists and inhaled steroids in asthma: meta-analysis of observational studies","volume":"47","author":"Hirst","year":"2010","journal-title":"J Asthma"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2222.2012.03965.x","article-title":"Severe asthma: future treatments","volume":"42","author":"O'Byrne","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaci.2011.04.039","article-title":"Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial","volume":"128","author":"Kerstjens","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.anai.2019.11.030","article-title":"Tiotropium in children and adolescents with asthma","volume":"124","author":"Murphy","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2021.01.007","article-title":"Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses","volume":"148","author":"Papi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.jfma.2025.01.021_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-023-01897-2","article-title":"Might it Be appropriate to anticipate the use of long-acting muscarinic antagonists in asthma?","volume":"83","author":"Cazzola","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jfma.2025.01.021_bib28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/cea.13702","article-title":"Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics","volume":"50","author":"Jabbal","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jfma.2025.01.021_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.11.004","article-title":"Interaction between corticosteroids and muscarinic antagonists in human airways","volume":"36","author":"Cazzola","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jfma.2025.01.021_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105801","article-title":"Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways","volume":"172","author":"Rogliani","year":"2021","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/all.15076","article-title":"Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications","volume":"77","author":"Agusti","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jfma.2025.01.021_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(14)70103-1","article-title":"Unlocking the quiet zone: the small airway asthma phenotype","volume":"2","author":"Lipworth","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jfma.2025.01.021_bib33","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/jcm13082320","article-title":"Managing small airway disease in patients with severe asthma: transitioning from the \u201csilent zone\u201d to achieving \u201cquiet asthma.\u201d","volume":"13","author":"Carpagnano","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jfma.2025.01.021_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1586\/eci.09.62","article-title":"Montelukast in the treatment of asthma and beyond","volume":"5","author":"Diamant","year":"2009","journal-title":"Expet Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.jfma.2025.01.021_bib35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2222.2003.01696.x","article-title":"Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites","volume":"33","author":"Mechiche","year":"2003","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaci.2012.12.1567","article-title":"Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review","volume":"131","author":"van der Wiel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.jfma.2025.01.021_bib37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.rmed.2005.10.025","article-title":"Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study)","volume":"100","author":"Nieto","year":"2006","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.jfma.2025.01.021_bib38","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3760\/cma.j.issn.0366-6999.20121888","article-title":"Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot study","volume":"126","author":"Gao","year":"2013","journal-title":"Chin Med J (Engl)."},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines\u2014recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jfma.2025.01.021_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of biologic therapy on the small airways asthma phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/ACI.0000000000000284","article-title":"Biologic therapy in the management of asthma","volume":"16","author":"McCracken","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.jfma.2025.01.021_bib43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1365-2222.2010.03576.x","article-title":"High\u2010affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma","volume":"40","author":"Den","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.200407-949OC","article-title":"Relationship of small airway chymase-positive mast cells and lung function in severe asthma","volume":"171","author":"Balzar","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines \u2010 recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jfma.2025.01.021_bib46","first-page":"4","article-title":"Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis","author":"Chong","year":"2023","journal-title":"Front Allergy"},{"issue":"7","key":"10.1016\/j.jfma.2025.01.021_bib47","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2021.01.029","article-title":"Real-life small airway outcomes in severe asthma patients receiving biologic therapies","volume":"9","author":"Chan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2500\/aap.2014.35.3741","article-title":"The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients","volume":"35","author":"Pasha","year":"2014","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.anai.2014.06.004","article-title":"Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study","volume":"113","author":"Tajiri","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib50","first-page":"97","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Invest Allergy Clin Immun"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.jfma.2025.01.021_bib52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/02770903.2024.2370012","article-title":"Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study","volume":"61","author":"Pianigiani","year":"2024","journal-title":"J Asthma"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib53","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"10.1016\/j.jfma.2025.01.021_bib54","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/23120541.00204-2019","article-title":"Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma","volume":"6","author":"Castro","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jfma.2025.01.021_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107535","article-title":"Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma","volume":"224","author":"Papi","year":"2024","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.anai.2023.07.021","article-title":"Real-life effects of dupilumab on airway oscillometry in severe uncontrolled asthma","volume":"131","author":"Chan","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.jfma.2025.01.021_bib58","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1111\/all.16214","article-title":"Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance","volume":"79","author":"Chan","year":"2024","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jfma.2025.01.021_bib59","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib61","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.jfma.2025.01.021_bib63","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jfma.2025.01.021_bib64","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaip.2019.09.036","article-title":"Efficacy of intravenous reslizumab in oral corticosteroid\u2013dependent asthma","volume":"8","author":"Nair","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"25","key":"10.1016\/j.jfma.2025.01.021_bib68","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib69","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0091-6749(98)70252-0","article-title":"Cytokine mRNA expression in asthma is not restricted to the large airways","volume":"101","author":"Minshall","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib70","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.jfma.2025.01.021_bib71","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/biomedicines9111550","article-title":"Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma","volume":"9","author":"Maglio","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jfma.2025.01.021_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jfma.2025.01.021_bib73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.01.016","article-title":"Mepolizumab improves small airway function in severe eosinophilic asthma","volume":"148","author":"Farah","year":"2019","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/all.13938","article-title":"Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma","volume":"75","author":"Antonicelli","year":"2020","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.jfma.2025.01.021_bib75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.jfma.2025.01.021_bib76","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jfma.2025.01.021_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001472","article-title":"Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma","volume":"10","author":"Chan","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"22","key":"10.1016\/j.jfma.2025.01.021_bib79","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.jfma.2025.01.021_bib81","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.jfma.2025.01.021_bib82","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","article-title":"Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study","volume":"40","author":"Menzies-Gow","year":"2023","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib83","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","article-title":"Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials","volume":"9","author":"Chaudhuri","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jfma.2025.01.021_bib84","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma","volume":"181","author":"Castro","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib85","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2021.09.004","article-title":"Bronchial thermoplasty: the heat that reprograms the airways?","volume":"148","author":"Chakir","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib86","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12890-018-0721-6","article-title":"Bronchial thermoplasty reduces gas trapping in severe asthma","volume":"18","author":"Langton","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.alit.2021.07.011","article-title":"A clinical and canine experimental study in small-airway response to bronchial thermoplasty: role of the neuronal effect","volume":"71","author":"Luo","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.jfma.2025.01.021_bib88","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejrad.2018.08.007","article-title":"Quantitative CT detects changes in airway dimensions and air-trapping after bronchial thermoplasty for severe asthma","volume":"107","author":"Konietzke","year":"2018","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.jfma.2025.01.021_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2018-0011OC","article-title":"Unraveling a clinical paradox: why does bronchial thermoplasty work in asthma?","volume":"59","author":"Donovan","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.jfma.2025.01.021_bib90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/resp.13439","article-title":"Measuring the effects of bronchial thermoplasty using oscillometry","volume":"24","author":"Langton","year":"2019","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.jfma.2025.01.021_bib91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12931-020-1313-6","article-title":"Resistance of the respiratory system measured with forced oscillation technique (FOT) correlates with bronchial thermoplasty response","volume":"21","author":"Goorsenberg","year":"2020","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.jfma.2025.01.021_bib92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S2213-2600(21)00536-1","article-title":"The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study","volume":"10","author":"Kraft","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jfma.2025.01.021_bib93","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/JAA.S200912","article-title":"Recent developments in bronchial thermoplasty for severe asthma","volume":"12","author":"Thomson","year":"2019","journal-title":"J Asthma Allergy"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:30:55Z","timestamp":1776155455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0929664625000373"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.021","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small airways dysfunction in severe asthma: Current treatment approaches and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}